Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Lomedeucitinib by Bristol-Myers Squibb for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval
Lomedeucitinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According to...
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Lomedeucitinib?
Lomedeucitinib is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase II program in Plaque Psoriasis (Psoriasis Vulgaris)....
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Lomedeucitinib?
Lomedeucitinib is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase II program in Plaque Psoriasis (Psoriasis Vulgaris)....